Underestimation of Risk of a BRCA1 or BRCA2 Mutation in Women With High-Grade Serous Ovarian Cancer by BRCAPRO: A Multi-Institution Study

PURPOSE: Identification of the 10% to 15% of patients with ovarian cancer who have germline BRCA1 or BRCA2 mutations is important for management of both patients and relatives. The BRCAPRO model, which estimates mutation likelihood based on personal and family cancer history, can inform genetic test...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Oncol
Autors principals: Daniels, Molly S., Babb, Sheri A., King, Robin H., Urbauer, Diana L., Batte, Brittany A.L., Brandt, Amanda C., Amos, Christopher I., Buchanan, Adam H., Mutch, David G., Lu, Karen H.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2014
Matèries:
ORIGINAL REPORTS
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4876344/
https://ncbi.nlm.nih.gov/pubmed/24638001
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2013.50.6055
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars